News & Events
< Back to News Overview
CogState Signs Second Agreement with Merck & Co., Inc.
09 / 07 / 2007
CogState Ltd (ASX:CGS) announced today that it is has signed a second contract with global research-driven pharmaceutical company, Merck & Co., Inc. for the use of CogState's cognitive testing technology and associated services in a clinical trial due to
start this year.
Mr. Brad O'Connor, chief executive officer of CogState, said, "As one of the largest pharmaceutical companies in the world, with an extensive CNS portfolio, Merck is a valued customer of CogState. This second contract is evidence of the strengthening relationship between the companies."
start this year.
Mr. Brad O'Connor, chief executive officer of CogState, said, "As one of the largest pharmaceutical companies in the world, with an extensive CNS portfolio, Merck is a valued customer of CogState. This second contract is evidence of the strengthening relationship between the companies."